The American Heart Association awarded its Clinical Research Prize for 2017 to Robert A. Harrington., M.D., of Stanford University School of Medicine, “for his leadership of research initiatives leading to the development of new anti-thrombotic agents that have dramatically improved everyday medical practice.”
Harrington received the prize during Sunday’s opening ceremony of the AHA Scientific Sessions 2017, a premier global exchange of the latest advances in cardiovascular science for researchers and clinicians, which was held at the Anaheim Convention Center. Association President John Warner, M.D., of the University of Texas Southwestern Medical Center at Dallas presented the prize, a citation and $5,000 honorarium, awarded annually for outstanding achievement in clinical cardiovascular science.
In presenting the prize, Warner lauded the California interventional cardiologist “for his creative development of novel approaches to the design and conduct of clinical trials focused on improving care of patients with coronary artery disease and its complications.”
Harrington is considered one of the most innovative investigators applying effective new approaches to the design and conduct of clinical trials.
“He has focused his investigative efforts on improving the care of coronary heart disease patients with blood-clotting complications, through a series of landmark studies that have become pivotal to gaining regulatory approval of anti-thrombotic medications across multiple indications,” Warner said.
“Dr. Harrington played a critical role in guiding the clinical development of these new programs, which have substantially increased our understanding of the use of a number of agents that are now part of routine medical practice.”